156 related articles for article (PubMed ID: 37866980)
1. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract][Full Text] [Related]
2. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
3. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
4. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
Califano I; Smulever A; Jerkovich F; Pitoia F
Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
[TBL] [Abstract][Full Text] [Related]
5. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
7. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
Iyer PC; Dadu R; Ferrarotto R; Busaidy NL; Habra MA; Zafereo M; Gross N; Hess KR; Gule-Monroe M; Williams MD; Cabanillas ME
Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
[No Abstract] [Full Text] [Related]
9. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
10. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in anaplastic thyroid cancer management.
Hamidi S; Maniakas A
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
[TBL] [Abstract][Full Text] [Related]
14. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836
[TBL] [Abstract][Full Text] [Related]
15. [Anaplastic thyroid carcinoma : new therapeutic approaches].
Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
[No Abstract] [Full Text] [Related]
18. Evaluating new treatments for anaplastic thyroid cancer.
Coca-Pelaz A; Rodrigo JP; Lopez F; Shah JP; Silver CE; Al Ghuzlan A; Menke-van der Houven van Oordt CW; Smallridge RC; Shaha AR; Angelos P; Mendenhall WM; Piazza C; Olsen KD; Corry J; Tufano RP; Sanabria A; Nuyts S; Nathan CA; Vander Poorten V; Dias FL; Suarez C; Saba NF; de Graaf P; Williams MD; Rinaldo A; Ferlito A
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1239-1247. PubMed ID: 36283091
[TBL] [Abstract][Full Text] [Related]
19. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
[TBL] [Abstract][Full Text] [Related]
20. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
